171 related articles for article (PubMed ID: 27206801)
1. Adverse event-related costs for systemic metastatic breast cancer treatment among female Medicaid beneficiaries.
Irwin DE; Masaquel A; Johnston S; Barnett B
J Med Econ; 2016 Nov; 19(11):1027-1033. PubMed ID: 27206801
[TBL] [Abstract][Full Text] [Related]
2. The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States.
Latremouille-Viau D; Chang J; Guerin A; Shi S; Wang E; Yu J; Ngai C
J Med Econ; 2017 Jan; 20(1):54-62. PubMed ID: 27603498
[TBL] [Abstract][Full Text] [Related]
3. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.
Hao Y; Li N; Fang AP; Koo V; Peeples M; Kageleiry A; Wu EQ; Guérin A
Adv Ther; 2016 Jun; 33(6):983-97. PubMed ID: 27216253
[TBL] [Abstract][Full Text] [Related]
4. Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis.
Li N; Hao Y; Koo V; Fang A; Peeples M; Kageleiry A; Wu EQ; Guérin A
J Med Econ; 2016; 19(4):414-23. PubMed ID: 27032967
[TBL] [Abstract][Full Text] [Related]
5. Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting.
Hurvitz S; Guerin A; Brammer M; Guardino E; Zhou ZY; Latremouille Viau D; Wu EQ; Lalla D
Oncologist; 2014 Sep; 19(9):901-8. PubMed ID: 25085897
[TBL] [Abstract][Full Text] [Related]
6. Patterns of treatment, healthcare utilization and costs by lines of therapy in metastatic breast cancer in a large insured US population.
Ray S; Bonthapally V; McMorrow D; Bonafede M; Landsman-Blumberg P
J Comp Eff Res; 2013 Mar; 2(2):195-206. PubMed ID: 24236561
[TBL] [Abstract][Full Text] [Related]
7. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.
Engel-Nitz NM; Johnson MP; Bunner SH; Ryan KJ
J Manag Care Spec Pharm; 2020 Jun; 26(6):729-740. PubMed ID: 32463768
[TBL] [Abstract][Full Text] [Related]
8. Costs associated with adverse events in patients with metastatic renal cell carcinoma.
Borker R
J Med Econ; 2014 Nov; 17(11):792-7. PubMed ID: 25116694
[TBL] [Abstract][Full Text] [Related]
9. Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe.
Campone M; Yang H; Faust E; Kageleiry A; Signorovitch JE; Zhang J; Gao H
J Med Econ; 2014 Dec; 17(12):837-45. PubMed ID: 25164472
[TBL] [Abstract][Full Text] [Related]
10. Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma.
Hagiwara M; Hackshaw MD; Oster G
J Med Econ; 2013 Nov; 16(11):1300-6. PubMed ID: 24004437
[TBL] [Abstract][Full Text] [Related]
11. Costs of adverse events among patients with HIV infection treated with nonnucleoside reverse transcriptase inhibitors.
Simpson KN; Chen SY; Wu AW; Boulanger L; Chambers R; Nedrow K; Tawadrous M; Pashos CL; Haider S
HIV Med; 2014 Sep; 15(8):488-98. PubMed ID: 24641448
[TBL] [Abstract][Full Text] [Related]
12. Costs associated with adverse events during treatment episodes for adult attention-deficit/hyperactivity disorder.
Schein J; Cloutier M; Bungay R; Gauthier-Loiselle M; Childress A
J Med Econ; 2024; 27(1):653-662. PubMed ID: 38602691
[TBL] [Abstract][Full Text] [Related]
13. Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy.
Shah A; Shah R; Kebede N; Mohamed A; Botteman M; Waldeck R; Hussain A
J Med Econ; 2020 Apr; 23(4):330-346. PubMed ID: 31835965
[No Abstract] [Full Text] [Related]
14. Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries.
Vouk K; Benter U; Amonkar MM; Marocco A; Stapelkamp C; Pfersch S; Benjamin L
J Med Econ; 2016 Sep; 19(9):900-12. PubMed ID: 27123564
[TBL] [Abstract][Full Text] [Related]
15. Antiretroviral Treatment Switching and Its Association With Economic Outcomes and Adverse Treatment Effects Among Commercially Insured and Medicaid-Enrolled Patients With HIV in the United States.
Korsnes JS; Goodwin BB; Murray M; Candrilli SD
Ann Pharmacother; 2016 Dec; 50(12):989-1000. PubMed ID: 27439947
[TBL] [Abstract][Full Text] [Related]
16. Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy.
Borghaei H; Yim YM; Guerin A; Pivneva I; Shi S; Gandhi M; Ionescu-Ittu R
Lung Cancer; 2018 May; 119():112-119. PubMed ID: 29656745
[TBL] [Abstract][Full Text] [Related]
17. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer.
Hassett MJ; O'Malley AJ; Pakes JR; Newhouse JP; Earle CC
J Natl Cancer Inst; 2006 Aug; 98(16):1108-17. PubMed ID: 16912263
[TBL] [Abstract][Full Text] [Related]
18. Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population.
Kruse GB; Amonkar MM; Smith G; Skonieczny DC; Stavrakas S
J Manag Care Pharm; 2008; 14(9):844-57. PubMed ID: 19006441
[TBL] [Abstract][Full Text] [Related]
19. Costs associated with adverse events for systemic therapies in metastatic melanoma.
Fu AZ; Li Z; Tang J; Mahmood S; Whisman T; Qiu Y
J Comp Eff Res; 2018 Sep; 7(9):867-879. PubMed ID: 30192155
[TBL] [Abstract][Full Text] [Related]
20. Economic burden of adverse events in patients with metastatic renal cell carcinoma.
Hagiwara M; Borker R; Oster G
Clin Ther; 2013 Dec; 35(12):1955-1963.e2. PubMed ID: 24290735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
